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Abstract
Background: SET domain containing protein 2 (SETD2) is a histone methyltransferase that is involved in
transcriptional elongation.
There is evidence that SETD2 interacts with p53 and selectively regulates its downstream genes. Therefore, it
could be implicated in the process of carcinogenesis. Furthermore, this gene is located on the short arm of
chromosome 3p and we previously demonstrated that the 3p21.31 region of chromosome 3 was associated with
permanent growth arrest of breast cancer cells. This region includes closely related genes namely: MYL3,
CCDC12, KIF9, KLHL18 and SETD2. Based on the biological function of these genes, SETD2 is the most likely
gene to play a tumour suppressor role and explain our previous findings.
Our objective was to determine, using quantitative PCR, whether the mRNA expression levels of SETD2 were
consistent with a tumour suppressive function in breast cancer. This is the first study in the literature to examine
the direct relationship between SETD2 and breast cancer.
Methods: A total of 153 samples were analysed.
The levels of transcription of SETD2 were determined using quantitative PCR and normalized against (CK19).
Transcript levels within breast cancer specimens were compared to normal background tissues and analyzed
against conventional pathological parameters and clinical outcome over a 10 year follow-up period.
Results: The levels of SETD2 mRNA were significantly lower in malignant samples (p = 0.0345) and decreased
with increasing tumour stage.
SETD2 expression levels were significantly lower in samples from patients who developed metastasis, local
recurrence, or died of breast cancer when compared to those who were disease free for > 10 years (p = 0.041).
Conclusion:  This study demonstrates a compelling trend for SETD2 transcription levels to be lower in
cancerous tissues and in patients who developed progressive disease. These findings are consistent with a possible
tumour suppressor function of this gene in breast cancer.
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Background
Histone-lysine N-methyltransferase (SETD2) is a protein
that methylates 'Lys-36' of histone H3. H3 'Lys-36' meth-
ylation represents a specific tag for epigenetic transcrip-
tional activation. [1]
We previously demonstrated that the 3p21.31 region of
chromosome 3 was associated with permanent growth
arrest of breast cancer cells. This region includes closely
related genes namely: MYL3, CCDC12, KIF9, KLHL18 and
SETD2. Based on the biological function of these genes,
SETD2 is the most likely gene to play a tumour suppressor
role and explain our previous findings [2].
SETD2 plays a role in chromatin structure modulation
during transcriptional elongation via its interaction with
hyperphosphorylated POLR2A. It also may act as a tran-
scription activator that binds to promoters. [3]
SETD2 was first implicated in Huntington's disease (HD).
Huntington's disease is a neurodegenerative disorder
characterized by loss of striatal neurons, is caused by an
expansion of a polyglutamine tract in the HD protein
Huntingtin. [4] This gene encodes a protein belonging to
a class of huntingtin interacting proteins characterized by
WW motifs. [5,6] This protein is a histone methyltrans-
ferase that is specific for lysine-36 of histone H3, and
methylation of this residue is associated with active chro-
matin. This protein also contains a novel transcriptional
activation domain and has been found associated with
hyperphosphorylated RNA polymerase II.
It has been established that Histone modifications, which
include acetylation, phosphorylation, methylation and
ubiquitination, play key roles in gene regulation. [7]
These modifications create both agonistic and antagonis-
tic signals that correlate with the transcriptional activity of
a gene, through engaging some protein complexes or
through changing the structure of chromatin to allow
access for RNA polymerase to initiate transcription. [1]
These Histone modifications could act as marking system
that is responsible for establishing and maintaining pro-
grams of gene expression during cellular differentiation.
Previous research has shown that SETD2 could interact
with p53 and selectively regulate the transcription factor
activity of p53. The interaction was dependent of C-termi-
nal region of SETD2, which contains the SET and WW
domains and the N-terminal trans-activation domain of
p53 [8]. This evidence demonstrated that SETD2 down-
regulated hdm29 (transcription subset gene) expression
by targeting its P2 promoter and then enhanced p53 pro-
tein stability. These findings suggest that SETD2 could
selectively regulate the transcription of subset genes via
cooperation with the transcription factor p53. [8] So,
hypothetically, increased SETD2 activity could enhance
the action of tumour suppressor gene P53 and therefore
have tumour suppressive function in human breast can-
cer.
Furthermore, SETD2 is located on the short arm of chro-
mosome 3 and this region has been associated with per-
manent growth arrest of the tumour cells. [2]
The aim of our study was to determine, using quantitative
PCR, whether the mRNA expression levels of SETD2 were
consistent with a tumour suppressive function in human
breast cancer. This is the first study in the literature to
examine the direct relationship between SETD2 and
breast cancer.
Methods
Patients & Samples
Institutional guidelines, including ethical approval and
informed consent, were followed. Breast cancer tissues (n
= 127) and normal background tissues (n = 33) were col-
lected immediately after excision during surgery, and
stored at -80°C until use. A consultant pathologist exam-
ined hematoxylin and eosin stained frozen sections to ver-
ify the presence of tumor cells in the collected samples.
Normal tissue was derived from the background breast
parenchyma of breast cancer patients within the study
group. All tissues were randomly numbered and the
details were only made known after all analyses were com-
pleted. All patients were treated according to local algo-
rithms of management following a multidisciplinary
discussion. Patients treated with breast-conserving surgery
received adjuvant radiotherapy. Those with hormone-sen-
sitive malignancy received tamoxifen. Fit patients with
node-positive breast cancer or hormone-insensitive large
and/or high grade cancer were offered adjuvant chemo-
therapy. Medical notes and histology reports were used to
extract clinico-pathological data (Table 1). A customized
database was established to record data.
Materials
RNA extraction kits and reverse transcription kits were
obtained from Sigma-Aldrich Ltd (Poole, Dorset, Eng-
land, UK). PCR primers were designed using Beacon
Designer (Palo Alto, CA) and synthesized by Sigma-
Aldrich. Custom made hot-start Master-mix for quantita-
tive PCR was obtained from Abgene (Surrey, England,
UK). [9,10]
Tissue Processing, RNA Extraction and cDNA Synthesis
Frozen sections of tissue were cut at a thickness of 5–10
mm and kept for routine histological analysis. Additional
15–20 sections were mixed and homogenized using a
hand-held homogenizer in ice-cold RNA extraction solu-
tion. The concentration of RNA was determined using UVBMC Cancer 2009, 9:290 http://www.biomedcentral.com/1471-2407/9/290
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spectrophotometry. Reverse transcription was carried out
using a reverse transcription kit with an anchored olig
(dT) primer supplied by Abgene, using 1 mg of total RNA
in a 96-well plate. The quality of cDNA was verified using
b-actin primers (Appendix 1).
Quantitative Analysis
The level of SETD2 transcripts from the above prepared
DNA were determined using real-time quantitative PCR
based on the Amplifluor technology, modified from a
method reported previously. [10] PCR primers were
designed using Beacon Designer software, but to the
reverse primer an additional sequence, known as the Z
sequence (5'-ACTGAACCTGACCGTACA-3') which is
complementary to the universal Z probe (Intergen, Inc.,
Oxford, UK) was added. The product expands one intron.
The primers used for each SETD2 are detailed in Appendix
1. The reaction was carried out using the following: Hot-
start Q-master mix (Abgene), 10 pmol of specific forward
primer, 1 pmol reverse primer which has the Z sequence,
10 pmol of FAM-tagged probe (Intergen, Inc.), and cDNA
from 50 ng of RNA. The reaction was carried out using the
IcyclerIQ (Bio-Rad Ltd, Hemel Heamstead, England, UK),
which is equipped with an optic unit that allows real-time
detection of 96 reactions, under the following conditions:
94°C for 12 min and 50 cycles of 94°C for 15 sec, 55°C
for 40 sec, and 72°C for 20 sec. The levels of the transcript
were generated from a standard that was simultaneously
amplified with the samples. Levels of SETD2 expression
were then normalized against CK19 expression, already
measured in these specimens, to correct for varying
amounts of epithelial tissue between samples. CK19 tran-
scripts were quantified as previously reported, [11] using
primers detailed in Appendix 1. With every PCR run, we
included a negative control without a template and a
known cDNA reference sample as a positive control.
Statistical Analysis
The Mann-Whitney U test was used for statistical analysis.
SETD2 transcript levels within breast cancer specimens
were compared to normal background tissues and ana-
lyzed against conventional pathological parameters and
clinical outcome over a 10 year follow-up period. In each
case the true copy number was used for statistical analysis
and hence samples were not classified as positive or nega-
tive. Statistical analysis was carried out using Minitab
(14.1) using a custom written macro (Stat 2005.mtw).
Results
The original number studied was 160 samples, but we had
to exclude some 7 samples as we had un-interpretable
results on analysis possibly due to sample contamination
and therefore these samples had to be excluded. SETD2
was found to be expressed in both benign and breast can-
cer specimens. Quantification of mRNA expression after
CK19 normalisation (Table 2) showed that levels of
SETD2 were significantly lower in malignant tissue sam-
ples compared to normal breast tissue (p = 0.0345). When
looking at the median values in table 2 we can also see
that levels are more than 23 time lower in malignant sam-
ples. This was also apparent when comparing normal tis-
sue to individual subgroups of malignant samples.
Firstly, we examined the correlation between expression
levels and tumour stage. We found a marked decrease in
SETD2 levels correlating with higher stages of tumour.
This was statistically significant when comparing TNM1 to
TNM3 (p = 0.038), TNM1 to TNM4 (p = 0.05), and TNM2
toTNM3 (p = 0.05). We then examined the correlation
with tumour grade. There was a noticeable trend with
lower levels correlating with increasing tumour grade;
however, this did not reach statistical significance (p =
0.16 and 0.18 when comparing grade 1 to grade 2 and 3
respectively).
We then examined the correlation with the Nottingham
Prognostic Index (NPI) and also noted a distinct decrease
in levels with NPI scores. This, however, was only statisti-
cally significant when comparing NPI1 to NPI 3 (p =
0.026).
Furthermore, SETD2 expression levels positively corre-
lated with progression of disease as levels were signifi-
Table 1: Clinical data showing number of patients in each 
category
Parameter Category Number
Node Status Node positive 65
Node negative 55
Tumor Grade 1 23
24 1
35 6
Tumor Type Ductal 94
Lobular 14
Medullary 2
Tubular 2
Mucinous 4
Others 4
TNM staging 1 69
24 0
37
44
Clinical Outcome Disease free 81
Alive With metastasis 7
With local recurrence 5
Died of breast cancer 20
Died of unrelated disease 7
ER receptor status ERą negative 26
ERą positive 62
ERβ negative 17
ERβ positive 71BMC Cancer 2009, 9:290 http://www.biomedcentral.com/1471-2407/9/290
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cantly lower in samples from patients who developed
metastasis, local recurrence, or died of breast cancer when
compared to those who were disease free for > 10 years (p
= 0.041) (median follow up 120 months). Table 3 illus-
trates the association between levels of expression and dis-
ease progression (CK19 normalized). Figure 1 and 2 show
Kaplan-Meier survival curves for overall and disease free
survival.
Data analysis also showed a correlation with ER status
(Estrogen receptors in Ductal carcinoma patients). Levels
of mRNA were significantly lower in ERb negative samples
when compared to positive (p = 0.025). Although data
analysis showed no statistically significant correlation
between SETD2 expression levels and ERą (p = 0.16).
Discussion
This is the first study in the literature to examine the direct
relationship between SETD2 mRNA expression and breast
cancer. Our findings demonstrate that this gene may have
a tumour suppressor function and its mRNA expression
could play a role as a prognostic indicator in human
breast cancer.
SETD2 (SET domain containing protein 2) is a histone
H3K36 trimethyltransferase protein that associates with
hyperphosphorylated RNA polymerase II and involves in
transcriptional elongation.
It has been established that regulation of chromatin struc-
ture modulates DNA replication and transcription. One
major mechanism that regulates the structure and func-
tion of chromatin is the covalent modification of his-
tones, [12,13] and this is linked to SETD2 function.
Several studies suggest that SETD2 and modified histones
are linked to transcriptional activation and repression,
DNA repair, and cell cycle regulation. [14,15]
Previous research showed that SETD2 could interact with
p53 and selectively regulate the transcription factor activ-
ity of p53. [8] Abnormalities of the p53 tumour suppres-
sor gene are among the most frequent molecular events in
human neoplasia. [16] Tumour suppressor p53 acts as
transcriptional activator, controlling the expression of a
variety of genes important in cell cycle regulation and
apoptosis. [17] It is composed of four identical subunits,
binds to a specific site on the DNA, and interacts with
transcription interaction factors, leading to the initiation
of transcription by RNA polymerase II. Furthermore,
SETD2 could be co-immunoprecipitated with p53 under
both exogenous and endogenous conditions. Therefore,
SETD2 over-expression augmented expression of the
Table 2: Levels of SETD2 mRNA expression (After CK19 normalisation) in each group of patients
Parameter subgroups No. Median Mean ± SD
All samples SETD2 all tissue 153 27 85547 ± 498012
Normal tissue 33 406 414434 ± 1106629
Tumor tissue 120 17 20950 ± 37626
NPI NPI1 68 11 8755 ± 26203
NPI2 37 24 16517 ± 55868
NPI3 15 3 318 ± 645
Grade Grade1 23 3 2592 ± 9686
Grade2 41 19 11942 ± 35360
Grade3 56 26 11457 ± 44706
TNM staging TNM1 69 4 8551 ± 29766
TNM2 40 42 8578 ± 24043
TNM3 7 0 174 ± 414
TNM4 4 221 679 ± 1081
Clinical outcomes Disease free 81 13 12239 ± 43466
Alive with Metastasis 7 2 1983 ± 5142
Local recurrence 5 930 3513 ± 5683
Died of Br Ca 20 16 698 ± 1741
ER receptor status ERą negative 7 24 4742 ± 18706
ERą positive 26 41 14278 ± 46482
ERβ negative 62 6 1698 ± 4441
ERβ positive 17 27 13353 ± 43908
Table 3: p values for SETD2 mRNA expression levels in relation 
to survival and disease progression
Parameter No. Disease free>10 years
Alive with Metastasis 6 p = 0.062
Local recurrence 4 p = 0.13
Died of Br Ca 16 p = 0.0026
All progressive disease 26 p = 0.041BMC Cancer 2009, 9:290 http://www.biomedcentral.com/1471-2407/9/290
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majority of p53 target genes and SETD2 suppression led to
their down-regulation. [8]
Such studies support and explain our finding of a compel-
ling trend for SETD2 mRNA levels to be lower in cancer-
ous tissues and in patients who developed progressive
disease (distal metastasis, local recurrence, or died of
breast cancer). These observations are consistent with a
possible tumour suppressor function of this gene in breast
cancer. Furthermore its location on chromosome 3p is
also consistent with such possible role. We also demon-
strated a statistically significant correlation with ERb sta-
tus which is a favourable prognostic indicator in human
breast cancer.
The strength of our report lies in the use of robust RT-PCR
methodology to analyze SETD2 mRNA expression in a
cohort of breast cancer patients with a long-term follow
up.
Conclusion
We are the first group to investigate SETD2 expression in
human breast cancer and identify a possible TSG function.
However there are several inherent limitations to our
study related to the relatively small sample size and lack
of data regarding protein expression of the gene studied.
Further research is required to confirm the role of SETD2
gene in the pathogenesis of breast cancer including immu-
nohistochemistry studies, in vitro experiments and the
preparation of animal models with suppressed SETD2
gene.
If our observations are confirmed by other studies, SETD2
could prove a valuable prognostic marker and its artificial
expression could represent a novel therapeutic strategy.
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Kaplan-Meier disease free survival analysis depending on the expression of SETD2 Figure 1
Kaplan-Meier disease free survival analysis depending on the expression of SETD2: .00 = low levels. 1.00 = high lev-
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Appendix 1
Primers for SETD2F1
tccaacagtctatggtgtga
Primers for SETDZr1
actgaacctgaccgtacatgagctgtgaaaatctgttg
Primers for SETD2F2
cagaagcttcaggaagagat
Primers for SETD2Zr2
actgaacctgaccgtacattggaagtactttgctttcc
Primers for SETD2F3
gaaaatgccatgttactttga
Primers for SETD2Zr3
actgaacctgaccgtacacacactgcattcgcttaata
Primers for SETD2F4
cccctgaagaagaagaaaat
Kaplan-Meier overall survival analysis depending on the expression of SETD2 Figure 2
Kaplan-Meier overall survival analysis depending on the expression of SETD2: .00 = low levels. 1.00 = high levels. P 
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Primers for SETDZr4
actgaacctgaccgtacaaagcaacacctttgaacatt, setd2Zr4
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